Trial results

A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes

NCT00838916 on ClinicalTrials.gov · last registry update 2017-01-09

Finished January 2012, after enrolling 779 people. Primary outcome, as filed: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52. albiglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P3

Drug

albiglutide

Tanzeum

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Enrollment

779

Started

2009-02

Primary completion

2012-01 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the albiglutide page for this molecule’s full trial and approval history.